Research Journal of Pharmacy and Technology
SCOPUS
  • Year: 2023
  • Volume: 16
  • Issue: 12

Antiviral Investigation of Cassia alata L. bioactive compounds for SARS-CoV-2 Mpro: In Silico approach

  • Author:
  • Dora Dayu Rahma Turista1, Viol Dhea Kharisma2,3, Arif Nur Muhammad Ansori4,5, Karina Ahmedovna Kardanova6, Islam Ruslanovich Aslanov6, Ibragim Muhadinovich Dotkulov6, Azret Zamirovich Apshev6, Amir Albertovich Dokshukin6, Maksim Rebezov7,8, Vikash Jakhmola5, Emdad Ullah9, Rahadian Zainul10,11,*
  • Total Page Count: 7
  • Page Number: 5610 to 5616

1Department of Biology Education, Faculty of Teacher Training and Education, Mulawarman University, Samarinda, Indonesia

10Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Negeri Padang, Padang, Indonesia

11Center for Advanced Material Processing, Artificial Intelligence, and Biophysic Informatics (CAMP-BIOTICS), Universitas Negeri Padang, Padang, Indonesia

2Department of Biology, Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia

3Division of Molecular Biology and Genetics, Generasi Biologi Indonesia Foundation, Gresik, Indonesia

4Postgraduate School, Universitas Airlangga, Surabaya, Indonesia

5Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India

6Medical Faculty, Kabardino-Balkarian State University, Nalchik, Russian Federation

7Department of Scientific Research, V. M. Gorbatov Federal Research Center for Food Systems, Moscow, Russian Federation

8Faculty of Biotechnology and Food Engineering, Ural State Agrarian University, Yekaterinburg, Russian Federation

9Department of Chemistry, Mississippi State University, Mississippi, United States

*Corresponding Author E-mail: rahadianzmsiphd@fmipa.unp.ac.id

Online Published on 07 February, 2024.

Abstract

SARS-CoV-2 has caused a prolonged COVID-19 pandemic since the end of December 2019 and is still ongoing now. Bioactive compounds can be used as drugs to treat infectious diseases. This study aims to determine C. alata as a drug candidate for COVID-19 through its inhibitory activity to Mpro SARS-CoV-2 in silico. Cassia alata bioactive compounds have the potential to be used as a candidate for anti-SARS-CoV-2 supported by the result of drug-likeness, ADMET, pharmacokinetics, binding affinity, and antiviral activity prediction. Further research needs to be carried out to make C. alata a drug for COVID-19.

Keywords

SARS-CoV-2, Mpro, Cassia alata, Bioactive compounds